Mycobacterium peregrinum: Bactericidal activity of antibiotics alone and in combination

Journal of Infection and Chemotherapy

Volumn 14, Issue 3, 2008, Pages 262-263

  Santos, Ana ^a,b   Cremades, Rosa ^a,b   Rodriguez, Juan Carlos ^a,b   Garcia Pachon, Eduardo ^a   Ruiz, Montserrat ^a,b   Royo, Gloria ^a,b  

^a Hospital General Universitario   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Drug resistance; Mycobacterium peregrinum

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN; TOBRAMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MYCOBACTERIUM PEREGRINUM; NONHUMAN;

EID: 45749155222     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0611-6     Document Type: Article

References (8)

1. Brown-Elliot BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-746.
2. Marie I, Heliot P, Roussel F, Herve F, Muir JF, Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymiositis treated with infliximab. Rheumatology (Oxford) 2005;44:1201-1202.
3. Short WR, Emery C, Bhandary M, O'Donnell JA. Misidentification of Mycobacterium peregrinum, the causal organism of a case of bacteremia and automatic implantable cardioverter defibrillator-associated infection, due to its unusual acid-fast staining characteristics. J Clin Microbiol 2005;43:2015-2017.
4. Rivera-Olivero IA, Guevara A, Escalona A, Oliver M, Perez-Alfonzo R, Piquero J, et al. Soft tissue infections due to non-tuberculous mycobacteria following mesotherapy. What is the price of beauty? Enferm Infecc Microbiol Clin 2006;24:302-306.
5. Cremades R, Santos A, Rodriguez JC, Garcia-Pachon E, Ruiz M, Royo G. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J Chemother 2008;20:43-47.
6. Fernandez-Roblas R, Esteban J, Cabria F, Lopez JC, Jimenez MS, Soriano F. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000;44:181-182.
7. Guillemin I, Sougakoff W, Cambau E, Revel-Viravau V, Moreau N, Jarlier V. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. Microbiology 1999;145:2527-2532.
8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.